Objective: To develop and evaluate Nevirapine (NVP) Extended release tablets for reducing the dosing frequency using Methylcellulose USP Methocel A15-LV and Hypromellose USP Methocel K4M Premium CR used as rate retarding polymers and Magnesium stearate as lubricant. Methods: Tablets were prepared by using roller compaction technique by employing Quality by Design (QbD) and Design of Experimentation (DoE) to study the effect of various process related parameters like Bulk density, Tapped density, Compressibility index, mesh size and in-vitro release data at 20th hour. Results: Obtained results had suggested that concentration of polymer had shown a potential effect over various process parameters and in-vitro drug release studies suggested that formulated tablets had shown a sustained release up to 24h when compared with marketed formulations. Conclusion: From the obtained results it can be concluded that formulation of Nevirapine ER Tablets employing QbD lead to a single dose per day in the management of HIV/AIDS.
INTRODUCTION
The basic concept of employing QbD approach in preparing any formulation is "Quality cannot be tested but should be built into it". 1 As per ICH, QbD can be defined as a systematic approach to develop a formulation with predefined objectives and special highlighting on process designing and quality risk management. 2 One of the major parameter in QbD is developing a design which includes, Equipment, excipients and manufacturing environments, any design space should get prior approval from regulatory bodies. In this design space various product variables are monitored in periodic manner for better quality of product. All these parameters will be assessed and conclusions will be reported. 3 Studies suggested that by employing QbD approach large scale productivity of the formulation can be improved, so that they can be released into the market. 4 Controlled or extended release is a system which provides a continuous release of the medicament for a pre-determined time interval. This infers that release of the medicament from a controlled system proceeds at a rate which is not only predictable but also reproducible. 5 Administration of these systems through oral route will be considered based on the disease, patient, duration of therapy and properties of the drug. Extended release systems controls the delivery of the medicament temporarily, it also makes an attempt to deliver the drug constantly at the deliver site. 6 It was reported that by formulating this controlled release systems the polymers obtained enhanced chain mobility and increased free macromolecular chains to diffuse through oral mucus layers and sustaining the release of drug from the formulation. 7 Nevirapine (NVP) is a Non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immune deficiency virus Type-1, which terminates the polymerase activity by getting attached to HIV-1 reverse transcriptase which results in disturbance of enzyme's catalytic site. In recent years research works demonstrated that NVP has shown prominent activity in HIV infected patients in combination of other drugs in therapy. NNRTI's acts by binding and blocking HIV reverse transcriptase and avoids HIV from replicating and resulting in the amount of HIV in blood. NVP reduces the risk of transmitting HIV to non-infected people as it binds to Reverse transcriptase (RT) and blocks RNA and DNA dependent polymerase activities by creating disturbances at enzymes catalytic site. 8 It was reported that in spite of its benefits treatment with NVP can cause severe hepatotoxicity and rashes. Studies suggested that NVP undergoes hepatic metabolism by cytochrome p450 and transformed into several hydroxylated metabolites and these metabolites are responsible to adverse effects when compared with parent molecule. [9] [10] The objective of present research was to develop an extended release tablet loaded with NVP employing QbD approach to reduce the dosing frequency and adverse effects caused by the metabolites in managing HIV/AIDS.
MATERIALS AND METHODS

Materials
Nevirapine was obtained as a gift sample from Apotex Research Pvt Ltd, Bengaluru. The other chemicals and excipients used in the study were of analytical grade.
Methods
Quality Target Product Profile for Nevirapine ER Tablets
In combination with other antiretroviral agents Nevirapine ER Tablets are indicated as an alternative for treatment of HIV-1 infection. A brief explanation about quality characteristics that affects formulation of Nevirapine ER Tablets is given in Table 1 . The results of the study confirmed that when these excipients, representing different functional uses in formulation, are combined with Nevirapine and were exposed to solid state stress conditions, no significant difference in impurity levels and (%) Assay was observed. Hence above mentioned.
Identification of critical and non-critical quality attributes (CQAs) for Nevirapine ER Tablets
CQA's were established based on the QTPP's defined in the above table for the development of Nevirapine Extended-Release Tablets. The attributes which have a potential effect on formulation variables during development of process which are related to the safety of the product formulated are termed as CQA. A brief explanation about CQA's are depicted in Table 2 .
CMAs of Excipient
The critical material attributes of all the excipients which have impact on the final formulation are listed and discussed below in Table 3 .
Hausner Ratio
Hausner ratio is an indirect way of accessing the ease of granules flow. It can be calculated by using bulk density and tapped density.
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Evaluation of compressed Nevirapine ER Tablets 400 mg
Weight Variation
Randomly 20 tablets were selected and weighed using a single balance. Standard deviations were calculated and checked with the standard pharmacopeial limits.
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Thickness
Tablets were selected randomly from all batches and measurement of thickness was done by using Vernier Calliper.
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Hardness
The strength of tablet is expressed in the form of tensile strength (Kg/cm 2 ). The amount of force required to break the tablets was measured by using a hardness tester. 15 
Friability
Randomly 20 tablets were selected and weighed from all the batches. The weighed tablets then placed in friabilator and then ran for 100 revolutions. After completion of 100 revolutions tablets were de-dusted, re-weighed and %friability was calculated.
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In vitro dissolution studies
Dissolution studies for extended release of NVP from the formulated tablets were done by USP type-2 dissolution apparatus using 6.8 pH. Phosphate buffer at 75 rpm and 37±0.5°C for 24 h. Quantity of drug dissolved in the selected buffer was estimated periodically by using ultra violet (UV) spectrophotometer (UV-1601 PC Shimadzu, Japan) at 244nm.
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Manufacturing process of Nevirapine ER Tablets using DoE
Experimental Design
A 2 3 2-Level factorial design was employed to evaluate the existing curvature effects one centre point. Force, gap and speed of the roller compactor were considered as independent variables. Granule bulk density, tap density, Carr's index and Dissolution at 20 h were used as dependent variables. Best fit model for statistical analysis was considered significant when P value was less than 0.05.
Preparation of Nevirapine ER Tablets
Based on the physico-chemical properties of NVP, roller compaction was selected as the most appropriate manufacturing process. In addition, the NVP physical properties (flow) suggested precluded direct compression as the method for formulating tablets. Hypromellose (Methocel K4M Premium) and Methylcellulose (Methocel A15-LV) were separately weighed, sieved and then mixed with NVP. The mixture was then lubricated by intragranular Magnesium stearate and roller compacted to yield active granules by milling the formed ribbon. Prior to compression one more step of lubrication was done by adding extra-granular (Magnesium stearate) and the mixture was forwarded to compression. Formulation chart for formulating NVP Tablets is shown in Table 4 .
Characterization of Granules
Bulk density
Measurement of Bulk density was done by pouring powder into a measuring cylinder through sieve # 20 and the initial weight was noted. The initial volume was termed as bulk volume.
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Tapped density
Tapped density is defined as the ratio between aggregate weights of granules to the tapped volume of powder. Measurement of the volume was done by tapping the granules 750 times. If the variance in volume exceeds 2%, further tapping should be done for 1250 times. It was conveyed in g/ml.
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Angle of Repose
Angle of repose was done by using powder flow tester. Angle of repose can be calculated by measuring the height and radius of the pile of granules. 13 
Compressibility index
It demonstrates the flow properties of the granules. It is conveyed in the form of % and can be calculated using bulk density and tapped density. 
RESULTS AND DISCUSSION
Optimization of Nevirapine ER Tablets
Optimization of Nevirapine ER Tablets was done by employing 2 3 2-Level factorial design. Force, gap and speed of the roller compactor were considered as independent variables. Granule bulk density, tap density, Carr's index, Granule size distribution (retains on #60 mesh ASTM) and Dissolution at 20 h were used as dependent variables, whereas levels -1, 0, +1 were used as ranges of variables respectively which is depicted in Table 5 and 6.
Experimental Design
The summary of data obtained of various responses for Nevirapine ER Tablets is presented in Table 7 .
Summary of results of regression analysis for responses
The summary of ANOVA analysis was given in Table 8a and 8b.
Effect of formulation variables on Bulk density of granules
As depicted in the Pareto chart (Figure 1a) , the significant factors affecting Bulk density of granules was roll pressure and roll gap. The contour plot for roll gap and roll pressure versus Bulk density of granules presented in the (Figure 1b) , showed that bulk density of granules increased with increasing roll pressure (positive effect) and decreases with increasing roller gap (Negative effect).
Effect of formulation variables on Tap density of granules
As depicted in the Pareto chart Figure 2a and Counter plot Figure 2b , no parameter had significant effect on the granules Tap density. 
Effect of formulation variables on Compressibility Index of granules
As depicted in the Pareto chart Figure 3a , the formulation variables which had shown a significant effect on Carr's index of granules was pressure applied on roll and gap between the roll. The contour plot for roll gap and roll pressure versus Carr's index of granules presented in the Figure 3b , showed that Carr's index of granules decreased with increasing pressure on the roll which can be termed as Negative effect and increases with enancing the gap between roll which can be termed as Positive effect.
Effect of formulation variables on granules PSD Above #60 ASTM mesh
As depicted in the Pareto chart Figure 4a , the important formulation variables afecting PSD Above #60 ASTM mesh was Roller force. The contour plot for PSD Above #60 ASTM mesh versus roll force and roll gap versus is presented in the Figure 4b , showed that. PSD Above #60 ASTM mesh increased with increasing roll force (positive effect).
Effect of formulation variables on Tablet dissolution at 20 H
Dissolution is one of CQAs of the drug product. Roller compaction process may affect the dissolution of the drug product. But form the Pareto chart and counterplot Figure 5a and 5b; it can be observed that, no parameter . Friability of tablets from all batches ranged from 0.03 to 0.135, which was well under limit.
In vitro dissolution studies
Dissolution studies for extended release of NVP were carried out in 900 ml of Ph. 6.8 phosphate buffer in USP Type-2 dissolution apparatus at 75 rpm and 37±0.5°C for 24 h. Results demonstrated that concentration of polymer had shown a potential influence over drug release from tablets. Tablets with low polymer concentration exhibited a immediate release when compared with reference product. With increase in concentration of polymer release of Nevirapine was in a controlled manner when compared to reference product which is depicted in Figure 6 .
CONCLUSION
The present research work foresees the applicability of QbD in formulating Nevirapine ER Tablets by using rate retarding polymers. From the results it was clearly evident that as the polymer concentration increases, there was a decline in the release of drug. Combination of polymers with other excipients do not interact with drug, which leads to sustained delivery of drug for longer periods. The optimized formulation from 2 3 2-Level factorial design can be used as a single dose per day in the management of HIV/AIDS. had significant impact on the amount of drug dissolved from the tablet at 20 h.
Characterization of Granules
Tablets were formulated by direct compression method and physicochemical properties of the granules were evaluated prior to compression. The granules of all the batches had shown good flow properties which is evident from the results depicted in Table 9 . Bulk and tap density were used to calculate compressability index where bulk density ranged from 0.481 to 0.581 and tapped density ranged from 0.771 to 0.799. The angle of repose value ranged from 25.09º to 29.82º, as the angle of repose was found below 30º it can be inferred that blend have good flow ability. The Hausner ratio ranged from 1.37 to 1.63. Form the reults it can be inferred that the granules posses free flowing property.
Evaluation of Tablets
Formulated tablets were evaluated for variation in weight, thickness, hardness and % friability. The results obtained from these tests were found to be satisfactory which are depicted in Table 10 . Results obtained from weight variation demonstrated that all the formulations
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